Christopher R. Anzalone
Net Worth

Last updated:

What is Christopher R. Anzalone net worth?

The estimated net worth of Dr. Christopher R. Anzalone is at least $177,983,001 as of 23 Dec 2024. He owns shares worth $74,798,043 as insider, has earned $75,814,958 from insider trading and has received compensation worth at least $27,370,000 in Arrowhead Pharmaceuticals, Inc..

What is the salary of Christopher R. Anzalone?

Dr. Christopher R. Anzalone salary is $1,610,000 per year as Chief Executive Officer, Pres & Director in Arrowhead Pharmaceuticals, Inc..

How old is Christopher R. Anzalone?

Dr. Christopher R. Anzalone is 56 years old, born in 1969.

What stocks does Christopher R. Anzalone currently own?

As insider, Dr. Christopher R. Anzalone owns shares in one company:

Company Title Shares Price per share Total value
Arrowhead Pharmaceuticals, Inc. (ARWR) Chief Executive Officer, Pres & Director 3,775,772 $19.81 $74,798,043

What does Arrowhead Pharmaceuticals, Inc. do?

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

ARWR logo
ARWR
Arrowhead Pharmaceuticals, Inc.
$19.81

Christopher R. Anzalone insider trading

Arrowhead Pharmaceuticals, Inc.

Dr. Christopher R. Anzalone has made 52 insider trades between 2008-2024, according to the Form 4 filled with the SEC. Most recently he sold 12,563 units of ARWR stock worth $246,109 on 23 Dec 2024.

The largest trade he's ever made was exercising 164,000 units of ARWR stock on 22 Aug 2008. As of 23 Dec 2024 he still owns at least 3,775,772 units of ARWR stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 12,563 $19.59 $246,109
Sale
Common Stock 5,799 $22.12 $128,274
Sale
Common Stock 8,260 $21.74 $179,572
Sale
Common Stock 12,653 $20.52 $259,640
Sale
Common Stock 37,769 $32.16 $1,214,651
Sale
Common Stock 19,730 $32.71 $645,368
Option
Common Stock 57,499 $14.54 $836,035
Option
Stock Option (right to buy) 57,499 $14.54 $836,035
Sale
Common Stock 5,318 $31.25 $166,188
Sale
Common Stock 4,634 $30.74 $142,449
Sale
Common Stock 12,000 $28.54 $342,480
Sale
Common Stock 24,338 $24.21 $589,223
Sale
Common Stock 31,523 $28 $882,644
Sale
Common Stock 26,232 $28.27 $741,579
Option
Stock Option (right to buy) 57,555 $4.75 $273,386
Option
Common Stock 57,755 $4.75 $274,336
Option
Stock Option (right to buy) 50,000 $2.01 $100,500
Sale
Common Stock 25,992 $40.02 $1,040,200
Option
Common Stock 50,000 $2.01 $100,500
Sale
Common Stock 24,008 $38.97 $935,592
Option
Common Stock 54,928 $2.01 $110,405
Sale
Common Stock 54,928 $39.14 $2,149,882
Option
Stock Option (right to buy) 54,928 $2.01 $110,405
Option
Common Stock 1,542 $31.21 $48,126
Option
Common Stock 39,082 $30.77 $1,202,553
Option
Stock Option (right to buy Common Stock) 2,501 $14.54 $36,365
Option
Common Stock 2,501 $14.54 $36,365
Sale
Common Stock 1,900 $50.51 $95,969
Sale
Common Stock 40,853 $53.11 $2,169,703
Option
Stock Option (right to buy Common Stock) 146,388 $5.19 $759,754
Option
Common Stock 146,388 $5.19 $759,754
Sale
Common Stock 42,153 $52.28 $2,203,759
Sale
Common Stock 61,482 $50.9 $3,129,434
Option
Stock Option (right to buy Common Stock) 11,806 $5.19 $61,273
Option
Common Stock 11,806 $5.19 $61,273
Option
Stock Option (right to buy Common Stock) 11,806 $5.19 $61,273
Option
Common Stock 11,806 $5.19 $61,273
Sale
Common Stock 9,223 $69.52 $641,183
Sale
Common Stock 3,074 $68.2 $209,647
Sale
Common Stock 25,857 $66.28 $1,713,802
Sale
Common Stock 6,989 $70.19 $490,558
Sale
Common Stock 14,857 $67.19 $998,242
Sale
Common Stock 50,000 $65.83 $3,291,500
Sale
Common Stock 15,000 $66.23 $993,450
Option
Common Stock 40,510 $5.45 $220,780
Option
Common Stock 40,510 $5.45 $220,780
Option
Common Stock (right to buy) 40,510 $5.45 $220,780
Option
Common Stock (right to buy) 40,510 $5.45 $220,780
Sale
Common Stock 38,676 $69.89 $2,702,988
Sale
Common Stock 38,676 $69.89 $2,702,988
Option
Stock Option (right to buy) 38,676 $2.01 $77,739
Option
Common Stock 38,676 $2.01 $77,739
Option
Stock Option (right to buy) 16,324 $2.01 $32,811
Option
Common Stock 16,324 $2.01 $32,811
Sale
Common Stock 16,324 $2.01 $32,811
Sale
Common Stock 100,000 $58.37 $5,836,500
Option
Stock Option (right to buy) 50,000 $9.9 $495,000
Option
Common Stock 50,000 $9.9 $495,000
Sale
Common Stock 50,000 $9.9 $495,000
Sale
Common Stock 100,000 $39.18 $3,918,000
Sale
Common Stock 83,333 $63.5 $5,291,646
Sale
Common Stock 83,333 $66.95 $5,579,144
Sale
Common Stock 100,000 $68.01 $6,801,300
Sale
Common Stock 12,033 $61.37 $738,405
Sale
Common Stock 37,967 $69.72 $2,646,907
Option
Stock Option (right to buy) 56,325 $5.2 $292,890
Sale
Common Stock 56,325 $5.2 $292,890
Option
Common Stock 56,325 $5.2 $292,890
Sale
Common Stock 20,000 $28.25 $565,000
Option
Stock Option (right to buy) 66,645 $5.1 $339,890
Option
Common Stock 66,645 $5.1 $339,890
Sale
Common Stock 66,645 $28.52 $1,900,715
Option
Stock Option (right to buy) 41,755 $29.04 $1,212,565
Option
Common Stock 41,755 $29.04 $1,212,565
Sale
Common Stock 41,755 $29.04 $1,212,565
Sale
Common Stock 4,250 $5.1 $21,675
Option
Stock Option (right to buy) 4,250 $5.1 $21,675
Option
Common Stock 4,250 $5.1 $21,675
Option
Stock Option (right to buy) 49,448 $2.32 $114,472
Option
Common Stock 49,448 $2.32 $114,472
Sale
Common Stock 50,000 $19.3 $965,000
Sale
Common Stock 90,000 $13.92 $1,252,800
Sale
Common STock 90,000 $14.07 $1,266,300
Sale
Common Stock 81,500 $14.65 $1,193,975
Sale
Common Stock 64,834 $14.45 $936,851
Sale
Common Stock 100,000 $14.45 $1,445,000
Sale
Common Stock 26,000 $7.4 $192,400
Sale
Common Stock 100,000 $7.41 $741,000
Sale
Common Stock 100,000 $7.41 $741,000
Sale
Common Stock 100,000 $7.41 $741,000
Option
Common Stock 15,772 $5.09 $80,279
Purchase
Common Stock 16,000 $6.32 $101,120
Purchase
Common Stock 10,000 $0.89 $8,900
Purchase
Common Stock 10,000 $0.89 $8,900
Purchase
Common Stock 164,000 $2 $328,000

Arrowhead Pharmaceuticals key executives

Arrowhead Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: